

Global RNAi Therapeutics Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/GF9D10F64172EN.html>

Date: January 2026

Pages: 149

Price: US\$ 4,480.00 (Single User License)

ID: GF9D10F64172EN

Abstracts

The global RNAi Therapeutics market size is expected to reach \$ 3141 million by 2032, rising at a market growth of 18.4% CAGR during the forecast period (2026-2032).

RNAi Therapeutics refers to drugs that harness RNA interference to silence disease-causing genes, primarily through small interfering RNA (siRNA), short hairpin RNA (shRNA), or related constructs. By selectively degrading target mRNA, RNAi enables precise, durable suppression of protein expression that is difficult to achieve with small molecules or antibodies. The field has matured from platform science to commercial reality, driven by advances in chemical stabilization, conjugation (e.g., receptor-mediated uptake), and clinically validated targets.

Upstream inputs include oligonucleotide chemistry, nucleotide building blocks, delivery technologies (conjugates, nanoparticles, vectors), and enabling IP around target discovery and bioinformatics. Manufacturing relies on specialized oligo synthesis, purification, and formulation under GMP. Downstream, RNAi therapeutics are developed by integrated biopharma companies or via partnerships with large pharma for late-stage trials and commercialization. End markets span metabolic and liver diseases, cardiovascular conditions, oncology, and rare genetic disorders, with hospitals and specialty clinics as primary channels.

Gross margins for RNAi therapeutics are structurally attractive but heterogeneous. Commercialized siRNA drugs can achieve ~70-85% gross margins as processes scale, yields improve, and conjugate-based delivery reduces formulation complexity. Margin headwinds include high COGS for complex chemistries, cold-chain logistics, and royalties tied to foundational IP. Early-stage programs show lower effective margins due to small batch sizes and high quality control intensity, while mature assets benefit from learning curves and supplier consolidation.

This report studies the global RNAi Therapeutics demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for RNAi Therapeutics, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of RNAi Therapeutics that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global RNAi Therapeutics total market, 2021-2032, (USD Million)

Global RNAi Therapeutics total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: RNAi Therapeutics total market, key domestic companies, and share, (USD Million)

Global RNAi Therapeutics revenue by player, revenue and market share 2021-2026, (USD Million)

Global RNAi Therapeutics total market by Type, CAGR, 2021-2032, (USD Million)

Global RNAi Therapeutics total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global RNAi Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Benitec Biopharma, Phio Pharmaceuticals, Rxi Pharmaceuticals, Arrakis Therapeutics, miRagen Therapeutics, Sylentis, Gradalis, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world RNAi Therapeutics market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global RNAi Therapeutics Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global RNAi Therapeutics Market, Segmentation by Type:

Subcutaneous Injection

Intravenous Infusion

Global RNAi Therapeutics Market, Segmentation by Molecular Modality:

Synthetic siRNA

shRNA / ddRNAi

miRNA Mimics / Inhibitors

bi-shRNA / bifunctional RNAi

Self-delivering RNAi

Global RNAi Therapeutics Market, Segmentation by Business Model:

Fully Integrated Biopharma

Platform-driven Licensing Model

Co-development / Profit-sharing Model

Others

Global RNAi Therapeutics Market, Segmentation by Application:

Cardiovascular Disease

Genetic Disorder

Cancer

Other

Companies Profiled:

Anylam Pharmaceuticals

Arrowhead Pharmaceuticals

Silence Therapeutics

Benitec Biopharma

Phio Pharmaceuticals

RXi Pharmaceuticals

Arrakis Therapeutics

miRagen Therapeutics

Sylentis

Gradalis

Sirnaomics

Silenseed

Silexion Therapeutics

Novartis

Novo Nordisk

Roche

Sanofi

Regeneron Pharmaceuticals

Key Questions Answered

1. How big is the global RNAi Therapeutics market?
2. What is the demand of the global RNAi Therapeutics market?
3. What is the year over year growth of the global RNAi Therapeutics market?
4. What is the total value of the global RNAi Therapeutics market?
5. Who are the Major Players in the global RNAi Therapeutics market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 RNAi Therapeutics Introduction
- 1.2 World RNAi Therapeutics Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World RNAi Therapeutics Total Market by Region (by Headquarter Location)
 - 1.3.1 World RNAi Therapeutics Market Size by Region (2021-2032), (by Headquarter Location)
 - 1.3.2 United States Based Company RNAi Therapeutics Revenue (2021-2032)
 - 1.3.3 China Based Company RNAi Therapeutics Revenue (2021-2032)
 - 1.3.4 Europe Based Company RNAi Therapeutics Revenue (2021-2032)
 - 1.3.5 Japan Based Company RNAi Therapeutics Revenue (2021-2032)
 - 1.3.6 South Korea Based Company RNAi Therapeutics Revenue (2021-2032)
 - 1.3.7 ASEAN Based Company RNAi Therapeutics Revenue (2021-2032)
 - 1.3.8 India Based Company RNAi Therapeutics Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 RNAi Therapeutics Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Major Market Trends

2 DEMAND SUMMARY

- 2.1 World RNAi Therapeutics Consumption Value (2021-2032)
- 2.2 World RNAi Therapeutics Consumption Value by Region
 - 2.2.1 World RNAi Therapeutics Consumption Value by Region (2021-2026)
 - 2.2.2 World RNAi Therapeutics Consumption Value Forecast by Region (2027-2032)
- 2.3 United States RNAi Therapeutics Consumption Value (2021-2032)
- 2.4 China RNAi Therapeutics Consumption Value (2021-2032)
- 2.5 Europe RNAi Therapeutics Consumption Value (2021-2032)
- 2.6 Japan RNAi Therapeutics Consumption Value (2021-2032)
- 2.7 South Korea RNAi Therapeutics Consumption Value (2021-2032)
- 2.8 ASEAN RNAi Therapeutics Consumption Value (2021-2032)
- 2.9 India RNAi Therapeutics Consumption Value (2021-2032)

3 WORLD RNAI THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS

- 3.1 World RNAi Therapeutics Revenue by Player (2021-2026)
- 3.2 Industry Rank and Concentration Rate (CR)

- 3.2.1 Global RNAi Therapeutics Industry Rank of Major Players
- 3.2.2 Global Concentration Ratios (CR4) for RNAi Therapeutics in 2025
- 3.2.3 Global Concentration Ratios (CR8) for RNAi Therapeutics in 2025
- 3.3 RNAi Therapeutics Company Evaluation Quadrant
- 3.4 RNAi Therapeutics Market: Overall Company Footprint Analysis
 - 3.4.1 RNAi Therapeutics Market: Region Footprint
 - 3.4.2 RNAi Therapeutics Market: Company Product Type Footprint
 - 3.4.3 RNAi Therapeutics Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: RNAi Therapeutics Revenue Comparison (by Headquarter Location)
 - 4.1.1 United States VS China: RNAi Therapeutics Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
 - 4.1.2 United States VS China: RNAi Therapeutics Revenue Market Share Comparison (2021 & 2025 & 2032)
- 4.2 United States Based Companies VS China Based Companies: RNAi Therapeutics Consumption Value Comparison
 - 4.2.1 United States VS China: RNAi Therapeutics Consumption Value Comparison (2021 & 2025 & 2032)
 - 4.2.2 United States VS China: RNAi Therapeutics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
- 4.3 United States Based RNAi Therapeutics Companies and Market Share, 2021-2026
 - 4.3.1 United States Based RNAi Therapeutics Companies, Headquarters (States, Country)
 - 4.3.2 United States Based Companies RNAi Therapeutics Revenue, (2021-2026)
- 4.4 China Based Companies RNAi Therapeutics Revenue and Market Share, 2021-2026
 - 4.4.1 China Based RNAi Therapeutics Companies, Company Headquarters (Province, Country)
 - 4.4.2 China Based Companies RNAi Therapeutics Revenue, (2021-2026)
- 4.5 Rest of World Based RNAi Therapeutics Companies and Market Share, 2021-2026

4.5.1 Rest of World Based RNAi Therapeutics Companies, Headquarters (Province, Country)

4.5.2 Rest of World Based Companies RNAi Therapeutics Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World RNAi Therapeutics Market Size Overview by Type: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 Subcutaneous Injection

5.2.2 Intravenous Infusion

5.3 Market Segment by Type

5.3.1 World RNAi Therapeutics Market Size by Type (2021-2026)

5.3.2 World RNAi Therapeutics Market Size by Type (2027-2032)

5.3.3 World RNAi Therapeutics Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY MOLECULAR MODALITY

6.1 World RNAi Therapeutics Market Size Overview by Molecular Modality: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Molecular Modality

6.2.1 Synthetic siRNA

6.2.2 shRNA / ddRNAi

6.2.3 miRNA Mimics / Inhibitors

6.2.4 bi-shRNA / bifunctional RNAi

6.2.5 Self-delivering RNAi

6.3 Market Segment by Molecular Modality

6.3.1 World RNAi Therapeutics Market Size by Molecular Modality (2021-2026)

6.3.2 World RNAi Therapeutics Market Size by Molecular Modality (2027-2032)

6.3.3 World RNAi Therapeutics Market Size Market Share by Molecular Modality (2027-2032)

7 MARKET ANALYSIS BY BUSINESS MODEL

7.1 World RNAi Therapeutics Market Size Overview by Business Model: 2021 VS 2025 VS 2032

7.2 Segment Introduction by Business Model

7.2.1 Fully Integrated Biopharma

7.2.2 Platform-driven Licensing Model

7.2.3 Co-development / Profit-sharing Model

7.2.4 Others

7.3 Market Segment by Business Model

7.3.1 World RNAi Therapeutics Market Size by Business Model (2021-2026)

7.3.2 World RNAi Therapeutics Market Size by Business Model (2027-2032)

7.3.3 World RNAi Therapeutics Market Size Market Share by Business Model (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World RNAi Therapeutics Market Size Overview by Application: 2021 VS 2025 VS 2032

8.2 Segment Introduction by Application

8.2.1 Cardiovascular Disease

8.2.2 Genetic Disorder

8.2.3 Cancer

8.2.4 Other

8.3 Market Segment by Application

8.3.1 World RNAi Therapeutics Market Size by Application (2021-2026)

8.3.2 World RNAi Therapeutics Market Size by Application (2027-2032)

8.3.3 World RNAi Therapeutics Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 Alnylam Pharmaceuticals

9.1.1 Alnylam Pharmaceuticals Details

9.1.2 Alnylam Pharmaceuticals Major Business

9.1.3 Alnylam Pharmaceuticals RNAi Therapeutics Product and Services

9.1.4 Alnylam Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

9.1.5 Alnylam Pharmaceuticals Recent Developments/Updates

9.1.6 Alnylam Pharmaceuticals Competitive Strengths & Weaknesses

9.2 Arrowhead Pharmaceuticals

9.2.1 Arrowhead Pharmaceuticals Details

9.2.2 Arrowhead Pharmaceuticals Major Business

9.2.3 Arrowhead Pharmaceuticals RNAi Therapeutics Product and Services

9.2.4 Arrowhead Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

9.2.5 Arrowhead Pharmaceuticals Recent Developments/Updates

9.2.6 Arrowhead Pharmaceuticals Competitive Strengths & Weaknesses

9.3 Silence Therapeutics

9.3.1 Silence Therapeutics Details

9.3.2 Silence Therapeutics Major Business

9.3.3 Silence Therapeutics RNAi Therapeutics Product and Services

9.3.4 Silence Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

9.3.5 Silence Therapeutics Recent Developments/Updates

9.3.6 Silence Therapeutics Competitive Strengths & Weaknesses

9.4 Benitec Biopharma

9.4.1 Benitec Biopharma Details

9.4.2 Benitec Biopharma Major Business

9.4.3 Benitec Biopharma RNAi Therapeutics Product and Services

9.4.4 Benitec Biopharma RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

9.4.5 Benitec Biopharma Recent Developments/Updates

9.4.6 Benitec Biopharma Competitive Strengths & Weaknesses

9.5 Phio Pharmaceuticals

9.5.1 Phio Pharmaceuticals Details

9.5.2 Phio Pharmaceuticals Major Business

9.5.3 Phio Pharmaceuticals RNAi Therapeutics Product and Services

9.5.4 Phio Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

9.5.5 Phio Pharmaceuticals Recent Developments/Updates

9.5.6 Phio Pharmaceuticals Competitive Strengths & Weaknesses

9.6 RXi Pharmaceuticals

9.6.1 RXi Pharmaceuticals Details

9.6.2 RXi Pharmaceuticals Major Business

9.6.3 RXi Pharmaceuticals RNAi Therapeutics Product and Services

9.6.4 RXi Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

9.6.5 RXi Pharmaceuticals Recent Developments/Updates

9.6.6 RXi Pharmaceuticals Competitive Strengths & Weaknesses

9.7 Arrakis Therapeutics

9.7.1 Arrakis Therapeutics Details

9.7.2 Arrakis Therapeutics Major Business

9.7.3 Arrakis Therapeutics RNAi Therapeutics Product and Services

9.7.4 Arrakis Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

9.7.5 Arrakis Therapeutics Recent Developments/Updates

- 9.7.6 Arrakis Therapeutics Competitive Strengths & Weaknesses
- 9.8 miRagen Therapeutics
 - 9.8.1 miRagen Therapeutics Details
 - 9.8.2 miRagen Therapeutics Major Business
 - 9.8.3 miRagen Therapeutics RNAi Therapeutics Product and Services
 - 9.8.4 miRagen Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.8.5 miRagen Therapeutics Recent Developments/Updates
 - 9.8.6 miRagen Therapeutics Competitive Strengths & Weaknesses
- 9.9 Sylentis
 - 9.9.1 Sylentis Details
 - 9.9.2 Sylentis Major Business
 - 9.9.3 Sylentis RNAi Therapeutics Product and Services
 - 9.9.4 Sylentis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.9.5 Sylentis Recent Developments/Updates
 - 9.9.6 Sylentis Competitive Strengths & Weaknesses
- 9.10 Gradalis
 - 9.10.1 Gradalis Details
 - 9.10.2 Gradalis Major Business
 - 9.10.3 Gradalis RNAi Therapeutics Product and Services
 - 9.10.4 Gradalis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.10.5 Gradalis Recent Developments/Updates
 - 9.10.6 Gradalis Competitive Strengths & Weaknesses
- 9.11 Sirnaomics
 - 9.11.1 Sirnaomics Details
 - 9.11.2 Sirnaomics Major Business
 - 9.11.3 Sirnaomics RNAi Therapeutics Product and Services
 - 9.11.4 Sirnaomics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.11.5 Sirnaomics Recent Developments/Updates
 - 9.11.6 Sirnaomics Competitive Strengths & Weaknesses
- 9.12 Silenseed
 - 9.12.1 Silenseed Details
 - 9.12.2 Silenseed Major Business
 - 9.12.3 Silenseed RNAi Therapeutics Product and Services
 - 9.12.4 Silenseed RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

- 9.12.5 Silenseed Recent Developments/Updates
- 9.12.6 Silenseed Competitive Strengths & Weaknesses
- 9.13 Silexion Therapeutics
 - 9.13.1 Silexion Therapeutics Details
 - 9.13.2 Silexion Therapeutics Major Business
 - 9.13.3 Silexion Therapeutics RNAi Therapeutics Product and Services
 - 9.13.4 Silexion Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.13.5 Silexion Therapeutics Recent Developments/Updates
 - 9.13.6 Silexion Therapeutics Competitive Strengths & Weaknesses
- 9.14 Novartis
 - 9.14.1 Novartis Details
 - 9.14.2 Novartis Major Business
 - 9.14.3 Novartis RNAi Therapeutics Product and Services
 - 9.14.4 Novartis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.14.5 Novartis Recent Developments/Updates
 - 9.14.6 Novartis Competitive Strengths & Weaknesses
- 9.15 Novo Nordisk
 - 9.15.1 Novo Nordisk Details
 - 9.15.2 Novo Nordisk Major Business
 - 9.15.3 Novo Nordisk RNAi Therapeutics Product and Services
 - 9.15.4 Novo Nordisk RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.15.5 Novo Nordisk Recent Developments/Updates
 - 9.15.6 Novo Nordisk Competitive Strengths & Weaknesses
- 9.16 Roche
 - 9.16.1 Roche Details
 - 9.16.2 Roche Major Business
 - 9.16.3 Roche RNAi Therapeutics Product and Services
 - 9.16.4 Roche RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.16.5 Roche Recent Developments/Updates
 - 9.16.6 Roche Competitive Strengths & Weaknesses
- 9.17 Sanofi
 - 9.17.1 Sanofi Details
 - 9.17.2 Sanofi Major Business
 - 9.17.3 Sanofi RNAi Therapeutics Product and Services
 - 9.17.4 Sanofi RNAi Therapeutics Revenue, Gross Margin and Market Share

(2021-2026)

9.17.5 Sanofi Recent Developments/Updates

9.17.6 Sanofi Competitive Strengths & Weaknesses

9.18 Regeneron Pharmaceuticals

9.18.1 Regeneron Pharmaceuticals Details

9.18.2 Regeneron Pharmaceuticals Major Business

9.18.3 Regeneron Pharmaceuticals RNAi Therapeutics Product and Services

9.18.4 Regeneron Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

9.18.5 Regeneron Pharmaceuticals Recent Developments/Updates

9.18.6 Regeneron Pharmaceuticals Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 RNAi Therapeutics Industry Chain

10.2 RNAi Therapeutics Upstream Analysis

10.3 RNAi Therapeutics Midstream Analysis

10.4 RNAi Therapeutics Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. World RNAi Therapeutics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
- Table 2. World RNAi Therapeutics Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
- Table 3. World RNAi Therapeutics Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
- Table 4. World RNAi Therapeutics Revenue Market Share by Region (2021-2026), (by Headquarter Location)
- Table 5. World RNAi Therapeutics Revenue Market Share by Region (2027-2032), (by Headquarter Location)
- Table 6. Major Market Trends
- Table 7. World RNAi Therapeutics Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
- Table 8. World RNAi Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
- Table 9. World RNAi Therapeutics Consumption Value Forecast by Region (2027-2032) & (USD Million)
- Table 10. World RNAi Therapeutics Revenue by Player (2021-2026) & (USD Million)
- Table 11. Revenue Market Share of Key RNAi Therapeutics Players in 2025
- Table 12. World RNAi Therapeutics Industry Rank of Major Player, Based on Revenue in 2025
- Table 13. Global RNAi Therapeutics Company Evaluation Quadrant
- Table 14. Head Office of Key RNAi Therapeutics Players
- Table 15. RNAi Therapeutics Market: Company Product Type Footprint
- Table 16. RNAi Therapeutics Market: Company Product Application Footprint
- Table 17. RNAi Therapeutics Mergers & Acquisitions Activity
- Table 18. United States VS China RNAi Therapeutics Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
- Table 19. United States VS China RNAi Therapeutics Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
- Table 20. United States Based RNAi Therapeutics Companies, Headquarters (States, Country)
- Table 21. United States Based Companies RNAi Therapeutics Revenue, (2021-2026) & (USD Million)
- Table 22. United States Based Companies RNAi Therapeutics Revenue Market Share

(2021-2026)

Table 23. China Based RNAi Therapeutics Companies, Headquarters (Province, Country)

Table 24. China Based Companies RNAi Therapeutics Revenue, (2021-2026) & (USD Million)

Table 25. China Based Companies RNAi Therapeutics Revenue Market Share (2021-2026)

Table 26. Rest of World Based RNAi Therapeutics Companies, Headquarters (Province, Country)

Table 27. Rest of World Based Companies RNAi Therapeutics Revenue (2021-2026) & (USD Million)

Table 28. Rest of World Based Companies RNAi Therapeutics Revenue Market Share (2021-2026)

Table 29. World RNAi Therapeutics Market Size by Type, (USD Million), 2021 & 2025 & 2032

Table 30. World RNAi Therapeutics Market Size Value by Type (2021-2026) & (USD Million)

Table 31. World RNAi Therapeutics Market Size by Type (2027-2032) & (USD Million)

Table 32. World RNAi Therapeutics Market Size by Molecular Modality, (USD Million), 2021 & 2025 & 2032

Table 33. World RNAi Therapeutics Market Size Value by Molecular Modality (2021-2026) & (USD Million)

Table 34. World RNAi Therapeutics Market Size by Molecular Modality (2027-2032) & (USD Million)

Table 35. World RNAi Therapeutics Market Size by Business Model, (USD Million), 2021 & 2025 & 2032

Table 36. World RNAi Therapeutics Market Size Value by Business Model (2021-2026) & (USD Million)

Table 37. World RNAi Therapeutics Market Size by Business Model (2027-2032) & (USD Million)

Table 38. World RNAi Therapeutics Market Size by Application, (USD Million), 2021 & 2025 & 2032

Table 39. World RNAi Therapeutics Market Size by Application (2021-2026) & (USD Million)

Table 40. World RNAi Therapeutics Market Size by Application (2027-2032) & (USD Million)

Table 41. Alnylam Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 42. Alnylam Pharmaceuticals Major Business

- Table 43. Alnylam Pharmaceuticals RNAi Therapeutics Product and Services
- Table 44. Alnylam Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 45. Alnylam Pharmaceuticals Recent Developments/Updates
- Table 46. Alnylam Pharmaceuticals Competitive Strengths & Weaknesses
- Table 47. Arrowhead Pharmaceuticals Basic Information, Manufacturing Base and Competitors
- Table 48. Arrowhead Pharmaceuticals Major Business
- Table 49. Arrowhead Pharmaceuticals RNAi Therapeutics Product and Services
- Table 50. Arrowhead Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 51. Arrowhead Pharmaceuticals Recent Developments/Updates
- Table 52. Arrowhead Pharmaceuticals Competitive Strengths & Weaknesses
- Table 53. Silence Therapeutics Basic Information, Manufacturing Base and Competitors
- Table 54. Silence Therapeutics Major Business
- Table 55. Silence Therapeutics RNAi Therapeutics Product and Services
- Table 56. Silence Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 57. Silence Therapeutics Recent Developments/Updates
- Table 58. Silence Therapeutics Competitive Strengths & Weaknesses
- Table 59. Benitec Biopharma Basic Information, Manufacturing Base and Competitors
- Table 60. Benitec Biopharma Major Business
- Table 61. Benitec Biopharma RNAi Therapeutics Product and Services
- Table 62. Benitec Biopharma RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 63. Benitec Biopharma Recent Developments/Updates
- Table 64. Benitec Biopharma Competitive Strengths & Weaknesses
- Table 65. Phio Pharmaceuticals Basic Information, Manufacturing Base and Competitors
- Table 66. Phio Pharmaceuticals Major Business
- Table 67. Phio Pharmaceuticals RNAi Therapeutics Product and Services
- Table 68. Phio Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 69. Phio Pharmaceuticals Recent Developments/Updates
- Table 70. Phio Pharmaceuticals Competitive Strengths & Weaknesses
- Table 71. RXi Pharmaceuticals Basic Information, Manufacturing Base and Competitors
- Table 72. RXi Pharmaceuticals Major Business
- Table 73. RXi Pharmaceuticals RNAi Therapeutics Product and Services
- Table 74. RXi Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market

Share (2021-2026) & (USD Million)

Table 75. RXi Pharmaceuticals Recent Developments/Updates

Table 76. RXi Pharmaceuticals Competitive Strengths & Weaknesses

Table 77. Arrakis Therapeutics Basic Information, Manufacturing Base and Competitors

Table 78. Arrakis Therapeutics Major Business

Table 79. Arrakis Therapeutics RNAi Therapeutics Product and Services

Table 80. Arrakis Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 81. Arrakis Therapeutics Recent Developments/Updates

Table 82. Arrakis Therapeutics Competitive Strengths & Weaknesses

Table 83. miRagen Therapeutics Basic Information, Manufacturing Base and Competitors

Table 84. miRagen Therapeutics Major Business

Table 85. miRagen Therapeutics RNAi Therapeutics Product and Services

Table 86. miRagen Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 87. miRagen Therapeutics Recent Developments/Updates

Table 88. miRagen Therapeutics Competitive Strengths & Weaknesses

Table 89. Sylentis Basic Information, Manufacturing Base and Competitors

Table 90. Sylentis Major Business

Table 91. Sylentis RNAi Therapeutics Product and Services

Table 92. Sylentis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 93. Sylentis Recent Developments/Updates

Table 94. Sylentis Competitive Strengths & Weaknesses

Table 95. Gradalis Basic Information, Manufacturing Base and Competitors

Table 96. Gradalis Major Business

Table 97. Gradalis RNAi Therapeutics Product and Services

Table 98. Gradalis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 99. Gradalis Recent Developments/Updates

Table 100. Gradalis Competitive Strengths & Weaknesses

Table 101. Sirnaomics Basic Information, Manufacturing Base and Competitors

Table 102. Sirnaomics Major Business

Table 103. Sirnaomics RNAi Therapeutics Product and Services

Table 104. Sirnaomics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 105. Sirnaomics Recent Developments/Updates

Table 106. Sirnaomics Competitive Strengths & Weaknesses

- Table 107. Silenseed Basic Information, Manufacturing Base and Competitors
- Table 108. Silenseed Major Business
- Table 109. Silenseed RNAi Therapeutics Product and Services
- Table 110. Silenseed RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 111. Silenseed Recent Developments/Updates
- Table 112. Silenseed Competitive Strengths & Weaknesses
- Table 113. Silexion Therapeutics Basic Information, Manufacturing Base and Competitors
- Table 114. Silexion Therapeutics Major Business
- Table 115. Silexion Therapeutics RNAi Therapeutics Product and Services
- Table 116. Silexion Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 117. Silexion Therapeutics Recent Developments/Updates
- Table 118. Silexion Therapeutics Competitive Strengths & Weaknesses
- Table 119. Novartis Basic Information, Manufacturing Base and Competitors
- Table 120. Novartis Major Business
- Table 121. Novartis RNAi Therapeutics Product and Services
- Table 122. Novartis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 123. Novartis Recent Developments/Updates
- Table 124. Novartis Competitive Strengths & Weaknesses
- Table 125. Novo Nordisk Basic Information, Manufacturing Base and Competitors
- Table 126. Novo Nordisk Major Business
- Table 127. Novo Nordisk RNAi Therapeutics Product and Services
- Table 128. Novo Nordisk RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 129. Novo Nordisk Recent Developments/Updates
- Table 130. Novo Nordisk Competitive Strengths & Weaknesses
- Table 131. Roche Basic Information, Manufacturing Base and Competitors
- Table 132. Roche Major Business
- Table 133. Roche RNAi Therapeutics Product and Services
- Table 134. Roche RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 135. Roche Recent Developments/Updates
- Table 136. Roche Competitive Strengths & Weaknesses
- Table 137. Sanofi Basic Information, Manufacturing Base and Competitors
- Table 138. Sanofi Major Business
- Table 139. Sanofi RNAi Therapeutics Product and Services

Table 140. Sanofi RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 141. Sanofi Recent Developments/Updates

Table 142. Sanofi Competitive Strengths & Weaknesses

Table 143. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 144. Regeneron Pharmaceuticals Major Business

Table 145. Regeneron Pharmaceuticals RNAi Therapeutics Product and Services

Table 146. Regeneron Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 147. Regeneron Pharmaceuticals Recent Developments/Updates

Table 148. Regeneron Pharmaceuticals Competitive Strengths & Weaknesses

Table 149. Global Key Players of RNAi Therapeutics Upstream (Raw Materials)

Table 150. Global RNAi Therapeutics Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. RNAi Therapeutics Picture

Figure 2. World RNAi Therapeutics Total Revenue: 2021 & 2025 & 2032, (USD Million)

Figure 3. World RNAi Therapeutics Total Revenue (2021-2032) & (USD Million)

Figure 4. World RNAi Therapeutics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Figure 5. World RNAi Therapeutics Revenue Market Share by Region (2021-2032), (by Headquarter Location)

Figure 6. United States Based Company RNAi Therapeutics Revenue (2021-2032) & (USD Million)

Figure 7. China Based Company RNAi Therapeutics Revenue (2021-2032) & (USD Million)

Figure 8. Europe Based Company RNAi Therapeutics Revenue (2021-2032) & (USD Million)

Figure 9. Japan Based Company RNAi Therapeutics Revenue (2021-2032) & (USD Million)

Figure 10. South Korea Based Company RNAi Therapeutics Revenue (2021-2032) & (USD Million)

Figure 11. ASEAN Based Company RNAi Therapeutics Revenue (2021-2032) & (USD Million)

Figure 12. India Based Company RNAi Therapeutics Revenue (2021-2032) & (USD Million)

Figure 13. RNAi Therapeutics Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)

Figure 16. World RNAi Therapeutics Consumption Value Market Share by Region (2021-2032)

Figure 17. United States RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)

Figure 18. China RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)

Figure 19. Europe RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)

Figure 20. Japan RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)

Figure 21. South Korea RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)

Figure 23. India RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of RNAi Therapeutics by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for RNAi Therapeutics Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for RNAi Therapeutics Markets in 2025

Figure 27. United States VS China: RNAi Therapeutics Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: RNAi Therapeutics Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World RNAi Therapeutics Market Size by Type, (USD Million), 2021 & 2025 & 2032

Figure 30. World RNAi Therapeutics Market Size Market Share by Type in 2025

Figure 31. Subcutaneous Injection

Figure 32. Intravenous Infusion

Figure 33. World RNAi Therapeutics Market Size Market Share by Type (2021-2032)

Figure 34. World RNAi Therapeutics Market Size by Molecular Modality, (USD Million), 2021 & 2025 & 2032

Figure 35. World RNAi Therapeutics Market Size Market Share by Molecular Modality in 2025

Figure 36. Synthetic siRNA

Figure 37. shRNA / ddRNAi

Figure 38. miRNA Mimics / Inhibitors

Figure 39. bi-shRNA / bifunctional RNAi

Figure 40. Self-delivering RNAi

Figure 41. World RNAi Therapeutics Market Size Market Share by Molecular Modality (2021-2032)

Figure 42. World RNAi Therapeutics Market Size by Business Model, (USD Million), 2021 & 2025 & 2032

Figure 43. World RNAi Therapeutics Market Size Market Share by Business Model in 2025

Figure 44. Fully Integrated Biopharma

Figure 45. Platform-driven Licensing Model

Figure 46. Co-development / Profit-sharing Model

Figure 47. Others

Figure 48. World RNAi Therapeutics Market Size Market Share by Business Model (2021-2032)

Figure 49. World RNAi Therapeutics Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 50. World RNAi Therapeutics Market Size Market Share by Application in 2025

Figure 51. Cardiovascular Disease

Figure 52. Genetic Disorder

Figure 53. Cancer

Figure 54. Other

Figure 55. World RNAi Therapeutics Market Size Market Share by Application
(2021-2032)

Figure 56. RNAi Therapeutics Industrial Chain

Figure 57. Methodology

Figure 58. Research Process and Data Source

I would like to order

Product name: Global RNAi Therapeutics Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/GF9D10F64172EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF9D10F64172EN.html>